CN106632174A - 牛磺酸抗坏血酸氢钙及其制备方法和应用 - Google Patents
牛磺酸抗坏血酸氢钙及其制备方法和应用 Download PDFInfo
- Publication number
- CN106632174A CN106632174A CN201611237896.0A CN201611237896A CN106632174A CN 106632174 A CN106632174 A CN 106632174A CN 201611237896 A CN201611237896 A CN 201611237896A CN 106632174 A CN106632174 A CN 106632174A
- Authority
- CN
- China
- Prior art keywords
- taurine
- ascorbic acid
- acid hydrogen
- hydrogen calcium
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 146
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 128
- 229960003080 taurine Drugs 0.000 title claims abstract description 73
- 239000011575 calcium Substances 0.000 title claims abstract description 59
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 235000010323 ascorbic acid Nutrition 0.000 title claims abstract description 58
- 239000011668 ascorbic acid Substances 0.000 title claims abstract description 58
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 58
- 239000001257 hydrogen Substances 0.000 title claims abstract description 48
- 229910052739 hydrogen Inorganic materials 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title abstract 5
- 229940072107 ascorbate Drugs 0.000 title abstract 5
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910001868 water Inorganic materials 0.000 claims abstract description 16
- 239000013078 crystal Substances 0.000 claims abstract description 13
- 239000000292 calcium oxide Substances 0.000 claims abstract description 10
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims abstract description 10
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940087373 calcium oxide Drugs 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 43
- 238000001035 drying Methods 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 4
- 235000006708 antioxidants Nutrition 0.000 abstract description 4
- 206010006451 bronchitis Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000001132 Osteoporosis Diseases 0.000 abstract description 3
- 235000013373 food additive Nutrition 0.000 abstract description 3
- 239000002778 food additive Substances 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 37
- 239000000047 product Substances 0.000 description 8
- 239000011718 vitamin C Substances 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 229910006069 SO3H Inorganic materials 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000010376 calcium ascorbate Nutrition 0.000 description 3
- 229940047036 calcium ascorbate Drugs 0.000 description 3
- 239000011692 calcium ascorbate Substances 0.000 description 3
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010755 Conjunctivitis viral Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3544—Organic compounds containing hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种新的物质牛磺酸抗坏血酸氢钙，其化学分子式为CaH(C6H7O6)(H2NCH2CH2SO3)2·H2O，分子量为482.51。所述牛磺酸抗坏血酸氢钙的制备方法包括以下步骤：(1)将氧化钙、抗坏血酸和牛磺酸溶于水中，进行化学反应；(2)充分反应后，在反应溶液中加入乙醇，析出牛磺酸抗坏血酸氢钙晶体。本发明制备得到的牛磺酸抗坏血酸氢钙可同时为人体补充钙、VC和牛磺酸，可作为补钙、VC和牛磺酸的抗氧保鲜剂，作为补钙、VC和牛磺酸的食品添加剂，以及用于治疗骨质疏松、感冒、支气管炎、癌症等疾病。
Description
技术领域
本发明涉及生物化工医药食品领域，特别是涉及牛磺酸抗坏血酸氢钙及其制备方法和应用。
背景技术
当今国内外生物化工医药食品市场上的抗坏血酸钙(Calcium Ascorbate)，早在1946年由美国研制成功，其分子式为Ca(C6H7O6)2·2H2O，分子量为426.34，按质量百分比含钙9.40％，含抗坏血酸82.16％，含结晶水8.44％，为白色或微黄色结晶粉末，白色结晶粉末易变成微黄色结晶粉末，溶于水后呈黄色溶液，不能用于制备滴眼液、口服液和针剂。
抗坏血酸C6H8O6(简称VC，又名维生素C)的主要作用是提高免疫力，预防癌症、心脏病、中风、保护牙齿和牙龈等。抗坏血酸具有的还原性可消除造成癌变的亚硝基和引起衰老的自由基，故有防衰老、抗癌、抗氧、抗坏血病、抗疲劳、消炎、消毒之功效，是食品、调味品和饮品的优良抗氧保鲜剂。抗坏血酸还是生物体主要的抗氧化剂，其功效是通过抗氧化作用而实现的。
牛磺酸(Taurine)，其分子式为H2NCH2CH2SO3H，具有促进婴幼儿脑组织和智力发育、提高神经传导和视觉机能、防止心血管病、影响脂类的吸收、改善内分泌状态、增强人体免疫、影响糖代谢、抑制白内障的发生发展、改善记忆的功能和维持正常生殖功能等作用。肝脏中牛磺酸的作用是与胆汁酸结合形成牛磺胆酸，牛磺胆酸对消化道中脂类的吸收是必需的，其能增加脂类和胆固醇的溶解性，解除胆汁阻塞，降低某些游离胆汁酸的细胞毒性，抑制胆固醇结石的形成，增加胆汁流量等。研究表明，牛磺酸具有一定的降血糖作用，且不依赖于增加胰岛素的释放。牛磺酸具有多种生理功能，是人体健康必不可少的一种营养素，可用于治疗感冒、发热、头痛、神经痛、风湿性关节炎、药物中毒、急慢性肝炎、脂肪肝、胆囊炎，还可用于治疗支气管炎，扁桃体炎、眼炎等感染性疾病。含牛磺酸的滴眼剂可用于治疗急性结膜炎、疱疹性结膜炎和病毒性结膜炎。
抗坏血酸钙虽然含钙和抗坏血酸，但不能为人体提供牛磺酸。而且，当今国内外市场上少见能同时补充钙、抗坏血酸和牛磺酸的保健品或药品，也未见牛磺酸抗坏血酸氢钙这一物质的相关报道。
发明内容
基于此，本发明的目的在于，提供牛磺酸抗坏血酸氢钙及其制备方法和应用，本发明的牛磺酸抗坏血酸氢钙可同时为人体补充钙、VC和牛磺酸，可作为补钙、VC和牛磺酸的抗氧保鲜剂，作为补钙、VC和牛磺酸的食品添加剂，以及用于治疗骨质疏松、感冒、支气管炎、癌症等疾病。
本发明由以下具体方案实现：
牛磺酸抗坏血酸氢钙，其化学分子式为CaH(C6H7O6)(H2NCH2CH2SO3)2·H2O，分子量为482.51。
进一步地，所述的牛磺酸抗坏血酸氢钙，按质量百分比含钙8.31％，含抗坏血酸36.30％，含牛磺酸51.46％，含结晶水3.73％。
本发明的牛磺酸抗坏血酸氢钙，又名牛磺酸VC氢钙，经质谱确认和化学分析法测定，其化学分子式为CaH(C6H7O6)(H2NCH2CH2SO3)2·H2O，分子量为482.51，按质量百分比含钙8.31％，含抗坏血酸36.30％，含牛磺酸51.46％，含结晶水3.73％，其纯度在99％以上(医药食品级)，为白色结晶粉末，可溶于水[6.26g CaH(C6H7O6)(H2NCH2CH2SO3)2·H2O/100ml，25℃]，溶于水呈无色溶液。
本发明的牛磺酸抗坏血酸氢钙应用广泛，可作为补钙、VC和牛磺酸的抗氧保鲜剂，作为补钙、VC和牛磺酸的食品添加剂，或作为壮骨补脑的保健品。所述牛磺酸抗坏血酸氢钙还能用于治疗骨质疏松、腿抽筋、感冒、支气管炎、哮喘、肺炎、肺癌、肝炎、肝癌、冠心病、糖尿病、高血压等疾病，可制成片剂(每片0.2g，每次1-2片，一日三次服用)、冲剂、胶囊、滴眼液、口服液或针剂。
牛磺酸抗坏血酸氢钙的制备方法，包括以下步骤：
(1)将氧化钙CaO、抗坏血酸C6H8O6和牛磺酸H2NCH2CH2SO3H溶于水中，进行化学反应；
(2)充分反应后，在反应溶液中加入乙醇，析出牛磺酸抗坏血酸氢钙晶体。
本发明的制备方法简单、易操作，化学反应在水溶液中进行，反应时间快，反应产物牛磺酸抗坏血酸氢钙在水中的溶解度高于其在乙醇中的溶解度，而乙醇是价格较低、易蒸发被除去的常用化学试剂，因此选择在反应溶液中加入乙醇来析出反应产物。所述制备方法合成牛磺酸抗坏血酸氢钙的成本为抗坏血酸价格的80％。
进一步地，所述步骤(1)中，氧化钙、抗坏血酸与牛磺酸的摩尔比为1:1:2。
进一步地，所述步骤(1)的化学反应在常温下进行。
进一步地，所述步骤(2)中加入的乙醇为无水乙醇，无水乙醇的浓度高，以较少的用量即可将反应产物析出，能减少试剂成本以及反应产物的损失。
进一步地，还包括步骤(3)：对步骤(2)所得的物料进行过滤和洗涤处理，得到牛磺酸抗坏血酸氢钙晶体。
进一步地，还包括步骤(4)：对步骤(3)所得的牛磺酸抗坏血酸氢钙晶体进行烘干处理，烘干处理后包装成品。
进一步地，在步骤(4)中，烘干处理在102～105℃温度下进行，能加快烘干效率，同时防止反应产物分解。
本发明所述的牛磺酸抗坏血酸氢钙可应用于医药食品领域。
为了更好地理解和实施，下面结合附图详细说明本发明。
附图说明
图1为本发明的牛磺酸抗坏血酸氢钙的制备方法流程图。
具体实施方式
请参阅图1，其是本发明的牛磺酸抗坏血酸氢钙的制备方法流程图。
实施例1
本实施例牛磺酸抗坏血酸氢钙的制备方法，包括以下步骤：
(1)称取原料氧化钙CaO 56.1g、抗坏血酸C6H8O6 176.1g和牛磺酸H2NCH2CH2SO3H250.2g，将原料溶于去离子水中，去离子水的用量能刚好完全溶解原料即可，常温下进行化学反应。
(2)充分反应后，在反应溶液中加入无水乙醇，析出牛磺酸抗坏血酸氢钙晶体。
(3)对步骤(2)所得的物料进行过滤和利用无水乙醇洗涤处理，得到牛磺酸抗坏血酸氢钙晶体。
(4)对步骤(3)所得的牛磺酸抗坏血酸氢钙晶体在105℃下进行烘干处理，烘干处理后称重，得到牛磺酸抗坏血酸氢钙328.0g，最后包装成品。
实施例2
本实施例牛磺酸抗坏血酸氢钙的制备方法，包括以下步骤：
(1)称取原料氧化钙CaO 28.0g、抗坏血酸C6H8O6 88.1g和牛磺酸H2NCH2CH2SO3H125.1g，将原料溶于去离子水中，去离子水的用量能刚好完全溶解原料即可，常温下进行化学反应。
(2)分反应后，在反应溶液中加入无水乙醇，析出牛磺酸抗坏血酸氢钙晶体。
(3)对步骤(2)所得的物料进行过滤和利用无水乙醇洗涤处理，得到牛磺酸抗坏血酸氢钙晶体。
(4)对步骤(3)所得的牛磺酸抗坏血酸氢钙晶体在102℃下进行烘干处理，烘干处理后称重，得到牛磺酸抗坏血酸氢钙168.8g，最后包装成品。
以上所述实施例仅表达了本发明的几种实施方式，其描述较为具体和详细，但并不能因此而理解为对发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围。
Claims (10)
1.牛磺酸抗坏血酸氢钙，其化学分子式为CaH(C6H7O6)(H2NCH2CH2SO3)2·H2O，分子量为482.51。
2.权利要求1所述的牛磺酸抗坏血酸氢钙，其特征在于：按质量百分比含钙8.31％，含抗坏血酸36.30％，含牛磺酸51.46％，含结晶水3.73％。
3.牛磺酸抗坏血酸氢钙的制备方法，包括以下步骤：
(1)将氧化钙、抗坏血酸和牛磺酸溶于水中，进行化学反应；
(2)充分反应后，在反应溶液中加入乙醇，析出牛磺酸抗坏血酸氢钙晶体。
4.根据权利要求3所述的牛磺酸抗坏血酸氢钙的制备方法，其特征在于：所述步骤(1)中，氧化钙、抗坏血酸与牛磺酸的摩尔比为1:1:2。
5.根据权利要求3或4任一项所述的牛磺酸抗坏血酸氢钙的制备方法，其特征在于：所述步骤(1)的化学反应在常温下进行。
6.根据权利要求3或4任一项所述的牛磺酸抗坏血酸氢钙的制备方法，其特征在于：所述步骤(2)中加入的乙醇为无水乙醇。
7.根据权利要求3或4任一项所述的牛磺酸抗坏血酸氢钙的制备方法，其特征在于：还包括步骤(3)：对步骤(2)所得的物料进行过滤和洗涤处理，得到牛磺酸抗坏血酸氢钙晶体。
8.根据权利要求7所述的牛磺酸抗坏血酸氢钙的制备方法，其特征在于：还包括步骤(4)：对步骤(3)所得的牛磺酸抗坏血酸氢钙晶体进行烘干处理，烘干处理后包装成品。
9.根据权利要求8所述的牛磺酸抗坏血酸氢钙的制备方法，其特征在于：在步骤(4)中，烘干处理在102～105℃温度下进行。
10.权利要求1所述的牛磺酸抗坏血酸氢钙在医药食品领域的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611237896.0A CN106632174A (zh) | 2016-12-28 | 2016-12-28 | 牛磺酸抗坏血酸氢钙及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611237896.0A CN106632174A (zh) | 2016-12-28 | 2016-12-28 | 牛磺酸抗坏血酸氢钙及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106632174A true CN106632174A (zh) | 2017-05-10 |
Family
ID=58832350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611237896.0A Pending CN106632174A (zh) | 2016-12-28 | 2016-12-28 | 牛磺酸抗坏血酸氢钙及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106632174A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103739579A (zh) * | 2013-12-20 | 2014-04-23 | 李玉成 | 柠檬酸氢抗坏血酸钙及其制备方法和应用 |
-
2016
- 2016-12-28 CN CN201611237896.0A patent/CN106632174A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103739579A (zh) * | 2013-12-20 | 2014-04-23 | 李玉成 | 柠檬酸氢抗坏血酸钙及其制备方法和应用 |
Non-Patent Citations (2)
| Title |
|---|
| 段文军等: "牛磺酸钙的合成研究", 《第一军医大学分校学报》 * |
| 段文军等: "牛磺酸钙的吸收利用实验研究", 《中国公共卫生》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102775340B (zh) | 以贝壳为钙源的焦谷氨酸钙合成方法 | |
| CN104447272A (zh) | 无水柠檬酸镁的生产方法 | |
| CN103739579A (zh) | 柠檬酸氢抗坏血酸钙及其制备方法和应用 | |
| CN104673865B (zh) | 具有降尿酸作用的秋刀鱼美拉德肽及其制备方法和用途 | |
| WO2015027565A1 (zh) | 左旋肉碱微囊粉及其制备方法 | |
| CN106632174A (zh) | 牛磺酸抗坏血酸氢钙及其制备方法和应用 | |
| CN104355989B (zh) | 一种苹果酸镁的制备方法 | |
| CN111568969B (zh) | 以多聚体多酚为主的荔枝皮提取物在制备α-淀粉酶抑制剂中的应用 | |
| CN104163877B (zh) | 硫酸软骨素的制备方法 | |
| CN104306398A (zh) | 负氢离子抗氧化剂和锌、硼元素补充剂的低成本制备方法 | |
| CN106699782A (zh) | 柠檬酸抗坏血酸氢钙锌及其制备方法和应用 | |
| CN105685744A (zh) | 一种功能饮料 | |
| CN101642476A (zh) | 有机硒灵芝孢子粉的生产方法 | |
| CN103919761B (zh) | 一种苯丙氨酸鳌合钙粉及加工方法 | |
| CN100534441C (zh) | 一种水产养殖用苗种活力快速恢复剂 | |
| CN110151746A (zh) | 一种果糖氨基酸营养液的制备方法 | |
| CN106699816A (zh) | 硫酸氢抗坏血酸亚铁及其制备方法和应用 | |
| CN105232541B (zh) | 可皆霉素在制备治疗糖尿病药物中的应用 | |
| CN106632173A (zh) | 硫酸氢抗坏血酸钾及其制备方法和应用 | |
| CN106699706A (zh) | 葡萄糖酸抗坏血酸钙及其制备方法和应用 | |
| CN106699704A (zh) | 硫酸氢抗坏血酸钠及其制备方法和应用 | |
| RU2554767C2 (ru) | Препарат для стимуляции обменных процессов и ростовой активности телят | |
| CN106699705A (zh) | 山梨酸抗坏血酸五钙及其制备方法 | |
| CN102172352B (zh) | 一种供注射用的硫辛酸组合物及其制备方法 | |
| CN108095084A (zh) | 一种大叶藻海参保健食品及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |